NDA 005378 · Ajenat Pharms
Desoxyn
Methamphetamine Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1943
Dec 31, 1943
Approved uses
1
Original approval plus efficacy supplements
Registered trials
142
7 Phase 3, 14 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 31, 1943 Original approval Other Important Information from FDA
4 products under this application
- DESOXYN · METHAMPHETAMINE HYDROCHLORIDE 15MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- DESOXYN · METHAMPHETAMINE HYDROCHLORIDE 10MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- DESOXYN · METHAMPHETAMINE HYDROCHLORIDE 5MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- DESOXYN · METHAMPHETAMINE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Methamphetamine" as an intervention, any sponsor and status, largest first.
- Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA UsersPivotal-lookingRecruiting
Centre hospitalier de l'Université de Montréal (CHUM)Academic, hospital or other
NCT05854667 · 440 participants (planned) · Start Dec 5, 2023 · Primary completion Dec 2027
Drug: Treatment as Usual plus Placebo; Treatment as Usual plus Placebo plus Contingency Management and 2 more · For: Methamphetamine Abuse; Methamphetamine-dependence; Addiction, Substance and 1 more
Sites: Vancouver, Canada; Fredericton, Canada; Toronto, Canada · 4 sites in all
- Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use DisorderPivotal-lookingCompleted
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT03078075 · 403 participants · Start May 5, 2017 · Primary completion Jul 3, 2019
Drug: Naltrexone: Vivitrol®; Placebo (PLB) Injectable and 2 more · For: Methamphetamine Use Disorder
Sites: Los Angeles, California; San Francisco, California; Minneapolis, Minnesota · 8 sites in all
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use DisorderPivotal-lookingActive, not recruiting
National Institute on Drug Abuse (NIDA)NIH
NCT06233799 · 360 participants (planned) · Start Jul 1, 2024 · Primary completion Oct 30, 2026
Drug: extended-release naltrexone (XR-NTX); extended release bupropion (BUP-XL) tablets (BUP-XL) and 2 more · For: Methamphetamine-dependence; Methamphetamine Abuse
Sites: Little Rock, Arkansas; Los Angeles, California; San Diego, California · 11 sites in all
- Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderPivotal-lookingRecruiting
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT07825857 · 228 participants (planned) · Start Oct 23, 2026 · Primary completion Jul 1, 2031
Drug: Tirzepatide; Placebo (saline) · For: Methamphetamine Use Disorder
Sites: Los Angeles, California; San Francisco, California; Tulsa, Oklahoma · 4 sites in all
- MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA UsersPivotal-lookingStatus unknown
Sir Run Run Shaw HospitalAcademic, hospital or other
NCT03830827 · 220 participants (planned) · Start Sep 1, 2020 · Primary completion Apr 30, 2021
Drug: Vortioxetine · For: Relapse; Cognitive Impairment; Depression
- Phase 2, Multi-Center Trial of Modafinil for Methamphetamine DependencePivotal-lookingCompleted
National Institute on Drug Abuse (NIDA)NIH
NCT00520286 · 210 participants · Start Dec 2007 · Primary completion Dec 2009
Drug: Modafinil; Placebo · For: Methamphetamine Dependence
Sites: San Diego, California; Tarzana, California; Torrance, California · 8 sites in all
- Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine DependencePivotal-lookingCompleted
National Institute on Drug Abuse (NIDA)NIH
NCT00687713 · 200 participants · Start May 2008 · Primary completion May 2011
Drug: Bupropion · For: Methamphetamine Dependence
Sites: Los Angeles, California; San Diego, California; San Francisco, California · 12 sites in all
- Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine UsersPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT03341078 · 176 participants · Start May 1, 2019 · Primary completion Oct 15, 2025
Drug: Ibudilast; Placebo Oral Tablet · For: Methamphetamine-dependence
Sites: Portland, Oregon
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Emotion regulation in substance use disorders: a systematic review and meta-analysis.
Stellern J, Xiao KB, Grennell E, et al. · Addiction 2023 · Meta-Analysis, Systematic Review
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
Siefried KJ, Acheson LS, Lintzeris N, et al. · CNS Drugs 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH, Walker R, Ling W, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.
McKetin R, Shoptaw S, Saunders L, et al. · JAMA Psychiatry 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Tardelli VS, Bisaga A, Arcadepani FB, et al. · Psychopharmacology (Berl) 2020 · Meta-Analysis, Systematic Review
- Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial.
Ezard N, Clifford B, Siefried KJ, et al. · Addiction 2025 · Randomized Controlled Trial, Multicenter Study
Sponsor: Ajenat Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.